{ "items": [ "\n\n
\n \n\n \n \n \n \n Awards and Appointments\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n5 May 2021
\n \n \n \nCongratulations to all our Biomedical Sciences students and Medicine students who have been awarded prizes during the 2020-2021 academic year.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n5 May 2021
\n \n \n \nOlder patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n5 May 2021
\n \n \n \nInvestigators at the University of Oxford, University of California San Francisco (UCSF), Brown University and the Mayo Clinic have joined forces to develop open-source technology platforms for a new generation of neurostimulation devices that not only provide stimulation to the brain but also sense, record, and stream brain activity.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n4 May 2021
\n \n \n \nProfessor Laurent Servais of the Department of Paeditrics writes for the Oxford Science Blog on why it is important that we become much more efficient in the diagnosis of treatable conditions and in the treatment of these diseases.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n4 May 2021
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Awards and Appointments\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n4 May 2021
\n \n \n \nSixth year Clinical Medical student, Ryan Purdy (Worcester College), placed first in the Royal College of Ophthalmology's annual Prize Examination.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n30 April 2021
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n30 April 2021
\n \n \n \nNeutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n28 April 2021
\n \n \n \nLudwig Cancer Research team build on its TAPS method to develop an alternative to costly whole-genome sequencing for the detection of DNA methylation.
\n \n\n \n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n28 April 2021
\n \n \n \nA clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n28 April 2021
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n23 April 2021
\n \n \n \nCOVID-19 infections fell significantly \u2013 by 65% - after a first dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines in this large community surveillance study.
\n \n\n \n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n23 April 2021
\n \n \n \nResearchers from the University of Oxford and their partners have today reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy of 77% over 12-months of follow-up.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n23 April 2021
\n \n \n \nData from the COVID-19 Infection Survey, a partnership between the University of Oxford, the Office of National Statistics (ONS) and the Department for Health and Social Care (DHSC), is the first to show the impact of vaccination on antibody responses and new infections in a large group of adults from the general population aged 16 years and older.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n23 April 2021
\n \n \n \nA study of more than 2,100 pregnant women across 18 countries worldwide has revealed that COVID-19 is associated with a higher risk of severe maternal and newborn complications than previously recognised.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n21 April 2021
\n \n \n \nGeneral anaesthesia should be more widely available for patients at the end of their lives, according to Oxford experts in ethics and anaesthesia, according to a paper published by Anaesthesia (a journal of the Association of Anaesthetists).
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n19 April 2021
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n19 April 2021
\n \n \n \nThough the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n15 April 2021
\n \n \n \nCOVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.
\n \n\n \n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n14 April 2021
\n \n \n \nResearchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.
\n \n\n \n \n